Literature DB >> 19861517

Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.

Manuel Luedeke1, Carmen M Linnert, Matthias D Hofer, Harald M Surowy, Antje E Rinckleb, Josef Hoegel, Rainer Kuefer, Mark A Rubin, Walther Vogel, Christiane Maier.   

Abstract

The somatic fusion of TMPRSS2 to ETS oncogenes is a common event in prostate cancer (PCa). We hypothesized that defects in DNA repair may lead to an increase of chromosomal rearrangements and thus to the occurrence of ETS oncogene fusion. We have previously conducted a genome-wide linkage analysis in TMPRSS2-ERG fusion-positive PCa families, revealing potential susceptibility loci on chromosomes 5q14, 9q21, 10q26, 11q24, 12q15, 13q12, 18q, and Xq27. In the present study, nine candidate genes from these regions were selected from the context of DNA repair and screened for mutations in TMPRSS2-ERG fusion-positive families. Thirteen nonsynonymous variants, 5 of which had a minor allele frequency of <0.05, were genotyped in 210 familial cases, 47 of which with a known TMPRSS2-ERG status, 329 sporadic cases, and 512 controls. Significant association of TMPRSS2-ERG fusion-positive PCa was found with rare variants in the genes for POLI [variant F532S: P = 0.0011; odds ratios (OR), 4.62; 95% confidence interval (95% CI), 1.84-11.56] and ESCO1 (variant N191S: P = 0.0034; OR, 4.27; 95% CI, 1.62-11.28). Additional findings, regardless of TMPRSS2-ERG status, were the overrepresentation of a rare BRCA2 variant (V2728I: P = 0.03; OR, 6.16; 95% CI, 1.19-32.00) in familial PCa and of a common allele of RMI1 (variant N455S: P = 0.02; OR, 1.33; 95% CI, 1.04-1.70) in unselected PCa cases. The DNA repair genes POLI and ESCO1 are proposed as susceptibility genes for TMPRSS2-ERG fusion-positive PCa that warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19861517     DOI: 10.1158/1055-9965.EPI-09-0772

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  32 in total

1.  Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.

Authors:  David J Gallagher; Angel M Cronin; Matthew I Milowsky; Michael J Morris; Jasmine Bhatia; Peter T Scardino; James A Eastham; Kenneth Offit; Mark E Robson
Journal:  BJU Int       Date:  2011-07-14       Impact factor: 5.588

2.  Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

Authors:  David J Gallagher; Mia M Gaudet; Prodipto Pal; Tomas Kirchhoff; Lisa Balistreri; Kinjal Vora; Jasmine Bhatia; Zsofia Stadler; Samson W Fine; Victor Reuter; Michael Zelefsky; Michael J Morris; Howard I Scher; Robert J Klein; Larry Norton; James A Eastham; Peter T Scardino; Mark E Robson; Kenneth Offit
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

Review 3.  Recurrent gene fusions in prostate cancer: their clinical implications and uses.

Authors:  Daphne Hessels; Jack A Schalken
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

4.  Role of rare variants in undetermined multiple adenomatous polyposis and early-onset colorectal cancer.

Authors:  Jérémie H Lefevre; Carolina Bonilla; Chrystelle Colas; Bruce Winney; Elaine Johnstone; Susan Tonks; Tammy Day; Katarzyna Hutnik; Abdelhamid Boumertit; Florent Soubrier; Rachel Midgley; David Kerr; Yann Parc; Walter F Bodmer
Journal:  J Hum Genet       Date:  2012-08-09       Impact factor: 3.172

5.  Cdk1-dependent destruction of Eco1 prevents cohesion establishment after S phase.

Authors:  Nicholas A Lyons; David O Morgan
Journal:  Mol Cell       Date:  2011-05-06       Impact factor: 17.970

6.  Translesion synthesis polymerases in the prevention and promotion of carcinogenesis.

Authors:  L Jay Stallons; W Glenn McGregor
Journal:  J Nucleic Acids       Date:  2010-09-22

7.  Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes.

Authors:  Kathryn L Penney; Andreas Pettersson; Irene M Shui; Rebecca E Graff; Peter Kraft; Rosina T Lis; Howard D Sesso; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-03-03       Impact factor: 4.254

8.  RNAi screening identifies KAT8 as a key molecule important for cancer cell survival.

Authors:  Shuang Zhang; Xianhong Liu; Yong Zhang; Ying Cheng; Yang Li
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

9.  Increased expression of ESCO1 is correlated with poor patient survival and its role in human bladder cancer.

Authors:  Shiying Zhang; Jianye Li; Gaobiao Zhou; Dawei Mu; Jingmin Yan; Jizhang Xing; Zhiyong Yao; Haibo Sheng; Di Li; Chao Lv; Bin Sun; Quan Hong; Heqing Guo
Journal:  Tumour Biol       Date:  2015-11-07

Review 10.  Y-family DNA polymerases and their role in tolerance of cellular DNA damage.

Authors:  Julian E Sale; Alan R Lehmann; Roger Woodgate
Journal:  Nat Rev Mol Cell Biol       Date:  2012-02-23       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.